Use of the cobas 4800 system for the rapid detection of toxigenic Clostridium difficile and methicillin-resistant Staphylococcus aureus

Moure, Raquel; Cañizares, Ángeles; Muiño, M. Matos; Lobato, Margarita; Fernández, Ana; Rodriguez, M.; Gude, María José; Tomás, María; Bou, Germán

doi:10.1016/j.mimet.2015.11.014

Cited by 6 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our large, prospective, multisite clinical investigation, we demonstrated that the cobas Cdiff test is a robust test for the detection of toxigenic C. difficile. Our results extend those reported previously by Moure and colleagues, who found that the (20). Also, we demonstrated the stability of sample storage, which will be useful for future test development of next-generation molecular and culture-based CDI diagnostics.…”

Section: Discussionsupporting

confidence: 89%

Evaluation of the cobas Cdiff Test for Detection of Toxigenic Clostridium difficile in Stool Samples

et al. 2017

View full text Add to dashboard Cite

Nucleic acid amplification tests (NAATs) are reliable tools for the detection of toxigenic from unformed (liquid or soft) stool samples. The objective of this study was to evaluate performance of the cobas Cdiff test on the cobas 4800 system using prospectively collected stool specimens from patients suspected of having infection (CDI). The performance of the cobas Cdiff test was compared to the results of combined direct and broth-enriched toxigenic culture methods in a large, multicenter clinical trial. Additional discrepancy analysis was performed by using the Xpert Epi test. Sample storage was evaluated by using contrived and fresh samples before and after storage at -20°C. Testing was performed on samples from 683 subjects (306 males and 377 females); 113 (16.5%) of 683 subjects were positive for toxigenic by direct toxigenic culture, and 141 of 682 subjects were positive by using the combined direct and enriched toxigenic culture method (reference method), for a prevalence rate of 20.7%. The sensitivity and specificity of the cobas Cdiff test compared to the combined direct and enriched culture method were 92.9% (131/141; 95% confidence interval [CI], 87.4% to 96.1%) and 98.7% (534/541; 95% CI, 97.4% to 99.4%), respectively. Discrepancy analysis using results for retested samples from a second NAAT (Xpert C. difficile/Epi test; Cepheid, Sunnyvale, CA) found no false-negative and 4 false-positive cobas Cdiff test results. There was no difference in positive and negative results in comparisons of fresh and stored samples. These results support the use of the cobas Cdiff test as a robust aid in the diagnosis of CDI.

show abstract

Section: Discussionsupporting

confidence: 89%

Evaluation of the cobas Cdiff Test for Detection of Toxigenic Clostridium difficile in Stool Samples

et al. 2017

View full text Add to dashboard Cite

show abstract

“…55 A similar approach has also been used for the detection of MRSA using the cobas®MRSA/SA test. 56 A magnetic barcode assay system was also the basis for a multiplexed detection platform for S. aureus and K. pneumoniae, 57 which utilized both magnetic nanoparticles and uorescent quantum dots (QDs) for the detection of the target bacteria (Fig. 6).…”

Section: Nucleic Acidsmentioning

confidence: 99%

Novel diagnostics for point-of-care bacterial detection and identification

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In this study, we evaluated the analytical and clinical performance of the cobas ® Liat ® Cdiff. We compared this clinical performance to a previously introduced cobas ® Cdiff test that allows for medium-throughput batched sample processing on the cobas ® 4800 System (cobas ® 4800 Cdiff) [ 21 , 27 ]. We hypothesized that the clinical performance of both cobas ® Cdiff tests would be equivalent.…”

Section: Introductionmentioning

confidence: 99%

Equivalent performance of the cobas® Cdiff test for use on the cobas® Liat® system and the cobas® 4800 system

Garg

Duncan

et al. 2017

EuJMI

View full text Add to dashboard Cite

Clostridium difficile infection is a significant health burden, and innovative solutions are needed to shorten time to diagnosis and improve infection control. We evaluated the performance of the cobas® Cdiff test for use on the cobas® Liat® System (cobas® Liat® Cdiff), a single-sample, on-demand, and automated molecular solution with a 20-min turnaround time. The limit of detection was 45–90 colony-forming units (CFUs)/swab for toxigenic strains that covered the most prevalent toxinotypes, including the hyper-virulent epidemic 027/BI/NAP1 strain. Using 442 prospectively collected clinical stool specimens, we compared the performance of the cobas® Liat® Cdiff to direct culture and to the cobas® Cdiff test on the cobas® 4800 System (cobas® 4800 Cdiff) – a medium-throughput molecular platform. The sensitivity and specificity of the cobas® Liat® Cdiff compared to direct culture were 93.1% and 95.1%, respectively, and this performance did not statistically differ from the cobas® 4800 Cdiff (P < 0.05). Direct correlation of the cobas® Liat® and cobas® 4800 Cdiff tests yielded overall percent agreement of 98.6%. The test performance, automation, and turnaround time of the cobas® Liat® Cdiff enable its use for on-demand and out-of-hours testing as a complement to existing batch testing solutions like the cobas® 4800 Cdiff.

show abstract

Use of the cobas 4800 system for the rapid detection of toxigenic Clostridium difficile and methicillin-resistant Staphylococcus aureus

Cited by 6 publications

References 25 publications

Evaluation of the cobas Cdiff Test for Detection of Toxigenic Clostridium difficile in Stool Samples

Evaluation of the cobas Cdiff Test for Detection of Toxigenic Clostridium difficile in Stool Samples

Novel diagnostics for point-of-care bacterial detection and identification

Equivalent performance of the cobas® Cdiff test for use on the cobas® Liat® system and the cobas® 4800 system

Contact Info

Product

Resources

About